title: Bortezomib-induced Sweet syndrome.
authors.affiliation: Department of Haematology, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium. laurent.knoops@bru.licr.org
authors.forename: Laurent
authors.initials: L
authors.lastname: Knoops
authors.forename: Aurore
authors.initials: A
authors.lastname: Jacquemain
authors.forename: Dominique
authors.initials: D
authors.lastname: Tennstedt
authors.forename: Ivan
authors.initials: I
authors.lastname: Theate
authors.forename: Augustin
authors.initials: A
authors.lastname: Ferrant
authors.forename: Eric
authors.initials: E
authors.lastname: Van den Neste
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003875:Drug Eruptions / Q000209:etiology*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D016463:Sweet Syndrome / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D005938:Glucocorticoids; D011719:Pyrazines; D000069286:Bortezomib; D008775:Methylprednisolone